Search The Medical Knowledge Base

Drug Details

OPILON

• Drug Class Description
  Selective a1 -blockers (alpha- blockers / alpha-adrenoceptor blocking drugs).
• Generic Name
  Thymoxamine [moxisylyte]
• Presentation
  A pale yellow film-coated tablet
• Description
  Each tablet contains moxisylyte hydrochloride 45.22mg (equivalent to moxisylyte base 40mg).
• Indications
  Moxisylyte is an alpha-adrenergic blocking agent. Opilon tablets are indicated in the short term control of the symptoms of primary Raynaud's phenomenon.
• Adult Dosage
  

  Oral administration.

  Adults:

  Initially one tablet to be taken four times a day. This may be increased to two tablets four times a day if initial response is poor. For patients exposed to the cold during the daytime, one tablet should be administered every three hours during the period when symptoms are most likely to occur. In the

• Child Dosage
  

  Not recommended.

• Elderly Dosage
  

  As for adults.

  No clinical or pharmacokinetic data specific to this age group are available. Whilst at normal dosage no problems have been reported, caution nevertheless is advised when Opilon tablets are prescribed in the elderly.

• Contra Indications
  

  Opilon tablets are contraindicated in those with a hypersensitivity to any of the ingredients or who have active liver disease.

• Special Precautions
  

  The alpha-adrenergic blocking action of Opilon tablets will produce a vasodilating effect which may theoretically potentiate the effect of a number of drugs used in the management of hypertension. In practice, with the recommended dosage of Opilon tablets, this has not been reported.

  Opilon tablets should be used with caution in diabetes as, theoretically, insulin requirements may be reduced. Tricyclic antidepressants may increase any hypotensive effect produced by alpha blockade.

• Interactions
  TCADs, antihypertensives
• Adverse Drug Reactions
  

  Occasionally, mild nausea, diarrhoea, vertigo, headache, facial flushing and rash may be encountered. These are, however, rare and transient.

  There have also been rare reports of hepatotoxicity, including cases of hepatitis and cholestatic jaundice, which are reversible on stopping treatment. Opilon tablets should be withdrawn promptly if hepatic dysfunction develops.